Jinyu (Alice) Kang

Jinyu (Alice) Kang

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4403129
-
person_outline Jinyu (Alice) Kang's MOST POPULAR ARTICLES
1-) Olaparib for metastatic castration-resistant prostate cancer New England Journal of Medicine 382 (22), 2091-2102, 2020
2-) Survival with olaparib in metastatic castration-resistant prostate cancer New England Journal of Medicine 383 (24), 2345-2357, 2020
3-) Abiraterone and olaparib for metastatic castration-resistant prostate cancer NEJM evidence 1 (9), EVIDoa2200043, 2022
4-) A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction The oncologist 21 (9), 1085-1090, 2016
5-) A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junctionMA Shah, JY Cho, IB Tan, NC Tebbutt, CJ Yen, A Kang, DS Shames, L Bu, ...The oncologist 21 (9), 1085-1090, 20161162016